Search
for

    Glossary BRAVE-AA1

    clinical trial for baricitinib treating alopecia areata

    BRAVE-AA1 is a clinical trial designed to evaluate the efficacy and safety of a medication called baricitinib for treating alopecia areata, an autoimmune condition that causes hair loss. The trial aims to determine how well baricitinib, a Janus kinase (JAK) inhibitor, can help regrow hair in individuals with this condition.

    Related Terms

    Research 10 of 1000+

    1. Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies Journal of the American Academy of Dermatology · 2024 · 2 citations
    2. 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial Journal of The American Academy of Dermatology · 2021 · 1 citations
    3. Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2 SKIN The Journal of Cutaneous Medicine · 2025
    4. Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2 Annales de dermatologie et de vénéréologie, FMC · 2023
    5. Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials JEADV Clinical Practice · 2024
    6. 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study Journal of The American Academy of Dermatology · 2021 · 1 citations
    7. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    8. 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2 Journal of the American Academy of Dermatology · 2023 · 1 citations
    9. 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2 Journal of the American Academy of Dermatology · 2024
    10. 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2 Journal of The American Academy of Dermatology · 2022 · 4 citations
    All research results →

    Learn 1

    1. Baricitinib JAK inhibitor pill used for severe alopecia areata

    Community 1

    1. How to deal with feeling ugly while balding but not brave enough to shave Reddit · 7 Apr 2026